Cancer-induced bone pain is abundant among advanced-stage cancer patients and arises from a primary tumor in the bone or skeletal metastasis of common cancer types such as breast, lung, or prostate cancer. Recently, antibodies targeting nerve growth factor (NGF) have been shown to effectively relieve neuropathic and inflammatory pain states in mice and in humans. Although efficacy has been shown in mice on a behavioral level, effectiveness in preventing pain-induced functional rearrangements in the central nervous system has not been shown. Therefore, we assessed longitudinal whole-brain functional connectivity using restingstate functional magnetic resonance imaging in a mouse model of cancer-induced bone pain. We found functional connectivity between major hubs of ascending and descending pain pathways such as the periaqueductal gray, amygdala, thalamus, and cortical somatosensory regions to be affected by a developing cancer pain state. These changes could be successfully prevented through prospective administration of a monoclonal anti-NGF antibody (mAb911). This indicates efficacy of anti-NGF treatment to prevent pain-induced adaptations in brain functional networks after persistent nociceptive input from cancer-induced bone pain. In addition, it highlights the suitability of resting-state functional magnetic resonance imaging readouts as an indicator of treatment response on the basis of longitudinal functional network changes.
Introduction
Common cancer types such as breast, lung, and prostate cancer have a high predisposition of forming skeletal metastasis in bones such as femur, tibia, ribs, and vertebrae. 11 Tumor formation in bones frequently leads to anemia, increased risk of fracture, susceptibility to infections, and in many cases to a severe pain state, impairing patient's quality of life. Cancer-induced bone pain is a complex pain state known to cause persistent pain, movement-evoked pain, and severe episodes of breakthrough pain, which are particularly difficult to manage. 29 Commonly, ongoing cancer pain is managed adhering to the World Health Organization's analgesic ladder in combination with adjuvant therapies such as bisphosphonates, nonsteroidal antiinflammatory drugs, opioids, radiotherapy, or surgical interventions. 50 Although these therapies often exert severe side effects especially on long-term use, they also fail to address spontaneous breakthrough pain. Therefore, effective treatment of cancerinduced bone pain is still not available.
To better understand mechanisms involved, a preclinical model of bone cancer pain has been developed by orthotopic implantation of tumor cells. 12, 23 The model was shown to reproduce clinical symptoms of cancer-induced bone pain including spontaneous and evoked pain, correlating with tumor growth and cancer-induced bone remodeling. 29 Besides osteoclast-mediated bone resorption, tumor acidosis, and mediators released by tumor-associated stromal cells, tumorinduced damage to peripheral nociceptors was found to be a major contributor of cancer pain. 39, 45 Nociceptive Ad and C fibers innervating the adult bone are to the largest extent tyrosine kinase A (TrkA) positive, the target receptor of the nerve growth factor (NGF). 30 Nerve growth factor-sequestering antibodies for treating cancer pain were found to be highly effective in reducing tumor-induced nerve sprouting, neuroma formation, and bone cancer pain in mice. 28, 46 Effective relieve from skeletal pain was further indicated in clinical studies in different disease states such as osteoarthritis and chronic lower back pain. 9 Along with these peripheral effects, cancer-induced bone pain shows very distinct neurochemical alterations in the central nervous system (CNS) at the level of the spinal cord such as overexpression of dynorphin and c-FOS, as well as astrocyte hypertrophy. 24 These effects could partly be prevented through application of anti-NGF treatment. 46 Whereas anti-NGF treatment efficacy is largely described assessing peripheral, behavioral, or spinal cord level readouts, its effects on the brain remain unknown. As the conscious experience of pain is ultimately generated in the brain, assessing peripheral effects of anti-NGF treatment on the brain in a cancer pain state might give further insights into how effective pain relieve is.
Therefore, we assessed whole-brain functional connectivity (FC) using resting-state functional magnetic resonance imaging (rs-fMRI) in a mouse model of bone cancer pain. Resting-state functional MRI infers FC based on the synchronicity of spontaneous activity across brain regions 4, 5, 13, 31 and poses a unique window for assessing the functional state of the brain and how it is affected by a disease state. 16, 18, 49 By assessing longitudinal FC, we evaluated efficacy of the anti-NGF antibody mAb911 to modulate changes in brain networks after a cancerinduced bone pain state in mice.
Material and methods

Animals and experimental design
Animal experiments were conducted in accordance with regulations of the Cantonal Veterinary Office in Zürich, Switzerland. Female C57BL/6 mice at 8 to 10 weeks of age were obtained from Janvier Labs (Laval, France). Mice were held in individually ventilated cages in a 12/12-hour alternating light/ dark cycle at 22 to 24˚C with unrestricted access to food and water, and experiments were conducted during the light cycle. They were allocated to groups, and groups were allocated to cages in a randomized fashion using R's sample function. 41 Separation of groups by cages was decided to prevent social transfer of pain, which has been previously described. 47 Female mice were chosen because of the higher prevalence of females to develop a chronic pain state. 22 Functional MRI experiments were performed at baseline (BL) before tumor inoculation (0 d.p.i.), 10 and 20 days post-injection (d.p.i.) of the tumor cells. Anti-NGF treatment and behavioral readouts of pain were performed in parallel. Treatment and behavioral readouts were initiated 1 week post-tumor inoculation (8 d.p.i.). Thereby, anti-NGF treatment was injected after completion of behavioral experiments. Experimental groups used in this study and their characteristics are indicated in Table 1 . An outline of the experimental design is indicated in Figure 1. 
Mouse model of bone metastasis
The mouse model of chronic pain from bone metastasis was adopted from previously published procedures and refined for our purposes. 23, 25 In short, EO771 breast cancer cells were cultured to 80% confluency in RPMI medium supplemented with 10% fetal bovine serum at 37˚C. Mice of the tumor-bearing groups (Tumor 1 Vehicle and Tumor 1 anti-NGF) were injected with 10 5 tumor cells in 10 mL in the medulla of the right tibia, whereas mice of the control groups (Sham 1 Vehicle and Sham 1 anti-NGF) were injected with 10-mL phosphate-buffered saline instead. Therefore, mice were anesthetized at 3% isoflurane in a 1:5 mixture of O 2 /air, the hair was removed, and the skin was disinfected on the injected leg. To access the medullary space, a hole was drilled through the tibial plateau using a 27-G needle. Proper location of the needle was verified in 2 planar x-ray radiographs (35 kW/10 s, 43 geometric magnification) of a 90å ngle using a Faxitron MX-20 digital radiography system. Cells were then slowly injected using a 27-G Kel-F hub needle on a Hamilton syringe, and 1-minute time was given for cells to accommodate in the medullary space before removing the needle. Postoperative pain was managed by subcutaneous (s.c.) injection of Temgesic (60 mg/kg). During the whole procedure, mice were placed on a feedback-controlled heating mat to maintain physiological body temperature.
Behavioral readouts of spontaneous pain behavior
Behavioral experiments were conducted in a blinded fashion every fifth day, starting 1 week after tumor inoculation (8, 13 , and 18 d.p.i.). Thereby, the animals were placed on a home-built mesh stand, enclosed in a 10 3 10 3 20-cm compartment. Blinding was ensured by random placing of the animals in the absence of the experimenter conducting behavioral studies. All mice were habituated for 2 3 1 hour before start of the study. Before every experiment, mice were additionally habituated for 30 minutes. Guarding and flinching behavior was analyzed over the period of 2 minutes by video recording. Guarding was defined as holding the paw aloft while ambulatory, and flinching was defined as holding the paw aloft while steady according to previously published procedures. 6, 28 Number of guarding and flinching incidences was assessed from the video after the experiment.
Animal preparation and anesthesia
For induction of anesthesia, mice were anesthetized using 4% isoflurane in a 1:5 mixture of O 2 /air for 4 minutes before endotracheal intubation using PE-50/10 polyethylene tubing while maintaining anesthesia at 2%. Mice were cannulated intravenously (i.v.) in the lateral tail vein using the tip of a 30-G needle, and the animal was placed on the MRI support before application of pancuronium bromide (0.05 mg/kg, s.c.) and medetomidine hydrochloride (0.1 mg/kg, i.v.) bolus. After 5 minutes, isoflurane anesthesia was reduced to 0.5% and combined with a medetomidine hydrochloride infusion (0.05 mg/kg/h, i.v.) during the course of acquisition. During experiments, mice were mechanically ventilated using a small animal ventilator at a rate of 80 breaths/min with a cycle of 25% inhalation and 75% exhalation and 1.8 mL inspiration volume. Functional data acquisition was consistently started 15 minutes after the start of medetomidine infusion to ensure reproducible physiological states. To reduce motion artefacts, mouse heads were fixed using bite and ear bars. Body temperature was monitored using a rectal probe and maintained at 36.5 6 0.1˚C during the All surgical procedures were performed on the right tibia. mAb911 was diluted in 50-mL physiological saline before injection. i.p., intraperitoneal; NGF, nerve growth factor; PBS, phosphate-buffered saline.
course of the experiments. On termination of MRI experiments, animals were recovered on a heating map while still ventilated at 1% isoflurane until the effect of pancuronium bromide has worn off.
2.5. Anti-nerve growth factor treatment using murine anti-nerve growth factor monoclonal antibody mAb911
Murine monoclonal anti-NGF antibody mAb911 was kindly provided by Pfizer Inc (Groton, CT). Treatment regime and dosing were adopted from previous publications, demonstrating the effectiveness of mAb911 to reduce cancer-induced bone pain. 46 Anti-NGF treatment (10 mg/kg, intraperitoneally) was initiated prospectively at 8 d.p.i. and repeated in intervals of 5 days after behavioral experiments.
Magnetic resonance imaging acquisition protocol
Magnetic resonance imaging experiments were conducted using a Biospec 94/30 small animal MR system with a 30-cm horizontal bore operating at 400 MHz (9.4 T). For excitation and signal reception, a cryogenic quadrature transmit/receive surface coil was used.
Resting-state functional magnetic resonance imaging
Functional data were acquired using a gradient-echo echoplanar imaging sequence sensitive to the blood-oxygen-level dependent (BOLD) contrast with the following parameters: field of view 5 16 3 8 mm 2 and matrix size 5 80 3 40, resulting in 200 3 200 mm 2 in-plane resolution, 18 slices, slice thickness 5 0.5 mm, repetition time 5 1000 ms, echo time 5 12 ms, bandwidth 5 200 kHz, and number of averages 5 1. Acquisition time was 15 minutes 20 seconds (920 repetitions) of which the first 20 were discarded and 900 were used for subsequent analysis. To prevent fold-over artefacts, one saturation slice was positioned at the base of the brain.
Data processing and statistical analysis
Functional scans were normalized to an MRI template (Australian Mouse Brain Mapping Consortium, http://www.imaging. org.au/AMBMC) using linear affine and nonlinear greedy SyN transformation (ANTs V2.1, http://picsl.upenn.edu/software/ ants/). Independent functional components were extracted on an individual level using Multivariate Exploratory Linear Optimized Decomposition of Independent Components (ME-LODIC 3 ), taking the mean EPI image as a reference. This process included 0.01 Hz high-pass filtering of the 4D data set, spatial smoothing with a 2 3 2-mm 2 kernel, and head motion correction using MCFLIRT. 26 Independent components were classified into physiological and nonphysiological components using an in-house classifier, 51 and nonphysiological components in the BOLD signal were regressed out using FIX (FMRIB's ICA-based Xnoiseifier, 20, 43 v1.06). Classifier accuracy was tested using a subset of 10 BL scans, yielding an accuracy A (A 5 TNR 1 TPR/2) of 72.5%, TNR and TPR indicating truepositive and true-negative discovery rate, respectively, for the applied threshold during analysis. Group-level independent components of BL scans were used as naive animal reference resting-state networks (RSNs) to analyze projection regions of seeds in the seed-based analysis approach.
Region of interest (ROI)-based network analysis of wholebrain connectivity was performed using an ROI template comprising 75 anatomical ROIs based on the reference atlas of the Allen Institute for Brain Sciences (AIBS). Using fslmaths, average BOLD timeseries were extracted from the normalized, filtered data. Pairwise Pearson correlation values were calculated between all ROI combinations to obtain subject-and session-specific correlation matrices. Fisher's Z-transformed correlation matrices were used in a linear mixed model analysis to test for group and session interaction effects (R, lme4 package). For the seed-based analysis, average timeseries were extracted from seeds and used in a general linear model analysis (fsl_glm) as a regressor. Resulting subject-and session-level voxelwise Z-score maps of seed projections were subsequently analyzed within target ROIs using previously described RSNs as ROIs in a linear mixed model analysis, accounting for multiple comparisons (R, lme4, multcomp packages).
Behavioral readouts of pain were analyzed using multiple t tests (one per time point), and statistical significance was corrected for multiple comparisons using the Holm-Sidak method. Descriptive statistics are indicated as mean 61 SD in all plots with a statistical significance level of P , 0.05. 
Behavioral readouts of spontaneous pain
A linear mixed model analysis indicated significant group and session interactions in the Tumor-Vehicle vs Control-Vehicle (P , 0.0003 for guarding and P , 0.0001 for flinching) and Tumor-anti-NGF vs Control-Vehicle (P , 0.04 for guarding and P , 0.1 for flinching). Control-anti-NGF vs Control-Vehicle was not significant in both readouts. Post hoc, we performed multiple t tests, one per session, to determine statistically significant differences at each time point (Fig. 2) . Guarding behavior was found to be elevated in Tumor 
Region of interest-based network analysis
Region of interest-based analysis of longitudinal rs-fMRI data revealed distinct rearrangement of FC patterns in tumor-bearing as compared to sham-operated mice on vehicle treatment (Fig.  3, upper triangle) . Interactions of amygdallar nuclei (Amg) with thalamic (Th) as well as midbrain (Mb) regions were found to be most significantly affected. A closer look on midbrain structures revealed FC changes to be mostly confined in motor-related areas and the periaqueductal gray (PAG). In addition, FCs to cortical areas (Ctx) were found to be affected, in particular interactions with temporal associative (TAc)/insular (IC) regions and the cingulate cortex (Cg). Furthermore, FC between the thalamus and cortical areas was specifically affected in somatosensory as well as temporal associative/IC regions (supplementary Figure 1 , available at http://links.lww.com/PAIN/A659). Less distinct but still significant changes were additionally observed between striatal (Str) and midbrain as well as thalamic regions. Prospective treatment of tumor-bearing mice using mAb911 successfully prevented previously observed effects of persistent pain on FC (Fig. 3, lower triangle) . Few remaining significant alterations were found in deep nuclei comprised in midbrain and hindbrain (Hb) regions. The distinct patterns of altered connectivities associated with tumor development were virtually absent in Tumor 1 anti-NGF animals.
Significant treatment effects of mAb911 are indicated in supplementary Figure 2 (upper triangle), comparing animals of the Tumor 1 Vehicle and Tumor 1 anti-NGF groups (available at http://links.lww.com/PAIN/A659). Functional connectivities responding to treatment overlapped to a large extent with FCs exhibiting significant changes due to tumor development ( Fig. 3 Figure 2 , lower triangle, available at http://links. lww.com/PAIN/A659). We did not find significant differences between the groups except minor effects on FC between midbrain, striatal and amygdallar regions indicating low significance and random distribution across the brain.
In summary, we found distinct patterns on FC alterations within main regions of ascending and descending pain pathways in the untreated tumor-bearing group. These FC rearrangements could be largely prevented after prospective mAb911 treatment, and significant treatment effects were found. Intrinsic effects of mAb911 treatment on brain functional networks appear to be largely absent, a least for the treatment regime applied.
Seed-based analysis
For analyzing effects of cancer-induced bone pain on FC and their modulation by anti-NGF treatment, a seed-based analysis was performed using the main nuclei of ascending and descending nociceptive pathways as seed regions. The regions were chosen according to previously described results of ROIbased network analysis (Fig. 3) in both hemispheres separately, in nuclei of the amygdala, anterior and posterior part of the PAG, thalamus, and the motor-related portion of the superior colliculus. Alterations of regional seed FC were analyzed within bilateral target reference RSNs derived from naive animals using an independent component analysis. 51 Statistical significance was assessed using a linear mixed model analysis testing for significant group and session interaction, corrected for multiple Figure 2 . Behavioral readouts of spontaneous pain behavior. Guarding and flinching was assessed during a period of 2 minutes. Statistical significance was tested post hoc per time point compared with Sham 1 Vehicle using t tests accounting for multiple comparisons (the Holm-Sidak method). Brackets indicate significant treatment effects, comparing Tumor 1 anti-NGF with Tumor 1 Vehicle (*P , 0.05, **P , 0.01, and ***P , 0.001). NGF, nerve growth factor. comparisons, which was conducted using false discovery rate correction.
Significant effects were found for FC between the amygdallar seed (l Amg) contralateral to the tumor site and thalamic (Th, P 5 0.004), dorsal hippocampal (dHp, P 5 0.006), and somatosensory (B1c, P 5 0.021) areas (Fig. 4) . Furthermore, FC between the anterior PAG (aPAG) seed and barrelfield 2 cortex (B2c, P 5 0.032), posterior PAG (pPAG) seed and limb cortex (Lc, P 5 0.032), as well as ipsilateral motor-related superior collicular (rSCm) seed and the amygdala (Amg, P 5 0.035) was found to be significantly affected in the Tumor 1 Vehicle group. These changes in FC could be prevented by treatment with anti-NGF antibodies, as the Tumor 1 anti-NGF group did not display altered FCs in these regions when compared with Sham 1 Vehicle animals. Functional connectivity of the contralateral amygdallar seed to the cingulate cortex indicated the same trend, although the effect did not reach statistical significance (P 5 0.136, data not shown). As a control, FC was analyzed using a seed in the ipsilateral amygdala (rAmg), a region that does not receive direct nociceptive input. Functional connectivity from the right amygdala to the thalamus, barrelfield 1 cortex, and dorsal hippocampus, the corresponding regions to those displaying altered FC to the left amygdala, was not affected by the developing tumor in the right leg (Th: P 5 0.334, B1c: P 5 0.479, and dHp: P 5 0.307, supplementary Figure 3 , available at http://links.lww.com/PAIN/A659), as Z-scores in respective regions were found to be stable in all groups and measurement sessions. Assessment of treatment effects at 20 d.p.i revealed that mAb911 administration prevented FC changes between the left amygdallar seed and the dorsal hippocampus (P 5 0.031) and barrelfield 1 cortex (P 5 0.013). Furthermore, FC between the aPAG seed and the barrelfield 2 cortex (P 5 0.004) as well as between the pPAG seed and the limb cortex (P 5 0.012) was significantly modulated by the treatment. Significant FC changes on a persistent pain from bone cancer that could be prevented through mAb911 administration are schematically visualized in Figure 5 . Affected connectivities are depicted with respective differences in Z-scores (DZ) comparing Tumor 1 Vehicle vs Sham 1 Vehicle animals, indicating effect sizes of FC differences induced by bone cancer pain that could be prevented through mAb911 administration.
For visualizing treatment effects of mAb911, FC at 20 d.p.i. was compared in animals of the Tumor 1 Vehicle and Tumor 1 anti-NGF groups vs the Sham 1 Vehicle group using an unpaired t tests on a voxel-by-voxel basis (fsl-randomise). Uncorrected tstatistical maps visualizing previously described effects indicate voxels within a reference RSN, where seed-based FC is increasing compared with Sham 1 Vehicle controls (Fig. 6) . Although Tumor 1 Vehicle animals consistently indicate reduced FC between seeds and reference RSNs compared with Sham 1 Vehicle animals, this reduction in FC could be significantly prevented in the Tumor 1 anti-NGF group.
Discussion
Using longitudinal rs-fMRI and behavioral readouts of spontaneous pain in a mouse model of cancer pain from bone metastasis, we assessed efficacy of the NGF-sequestering antibody mAb911 to prevent cancer-induced bone pain. The primary molecular target of NGF is TrkA, to which it binds with high affinity, leading to the formation of homodimers. 10 More recent findings suggest NGF binding to p75 NTR , forming a heterodimer that is presented to TrkA.
1 Formation of such homodimer and heterodimer leads to activation of secondary-messenger cascades, modulating expression patterns of receptors and ion channels on peripheral nerve endings, and induce sensitization through a variety of neurotransmitters. 34 In addition, NGF induces sprouting and hyperinnervation of bones in metastatic bone diseases leading to the development of skeletal pain. 32 Although there is some knowledge on pathways affected by NGF, the exact molecular mechanisms and cell-type-specific expression patterns are still not clear.
The effects of NGF on peripheral nociceptors indicate fast sensitization of neurons towards chemical, mechanical, and thermal stimuli, which translate into prolonged alterations of fibers affecting CNS function.
2 Anti-NGF treatment has been shown to prevent such effects, as typical neurochemical changes in the spinal cord as a result of cancer-induced bone pain could be prevented. 46 Furthermore, anti-NGF treatment has been shown to be effective in a rat model of spinal cord injury, in which anti-NGF antibodies successfully suppressed mechanical hyperalgesia and increased responsiveness of wide-dynamic-range neurons in the spinal cord. 21 Nevertheless, studies indicating direct effects of NGF and anti-NGF treatment on the CNS remain sparse, probably due to the fact that target receptor expression is largely limited to peripheral nociceptors both in mammals and rodents. 35, 48 Moreover, direct effects are expected to be minimal due to poor CNS penetration of IgG molecules (.0.1% 38 ), whereas circulating concentrations are much higher. Therefore, effects of anti-NGF treatment in the CNS arise most likely from altered peripheral nociceptive processing rather than direct central action.
Along the lines of these results, our findings indicate efficacy of anti-NGF treatment to prevent FC in the brain after cancerinduced bone pain. We have shown alterations in major hubs of ascending and descending pain pathways. 14, 33 In particular, we found profound alterations affecting connections from the contralateral amygdallar nuclei to cortical somatosensory (B1c, B2c, and Lc) and limbic structures such as cingulate, temporal associative, and insular cortex as well as the midbrain. Midbrain structures indicated altered connectivities mostly in motor-related areas, likely reflecting impaired motor function of Figure 4 . Seed-based correlations were analyzed in regions of interest, plotting Z-scores as group averages. Projections of the left amygdallar seed (L Amg) to the thalamus (Th), dorsal hippocampus (dHp), and the barrelfield 1 cortex (B1c) indicate FC changes in Tumor 1 Vehicle animals, whereas other groups were not altered. Furthermore, projections of the right superior colliculus seed (R SCm) to the amygdalar RSN, anterior periaqueductal gray (aPAG) seed to the barrelfield 2 cortex (B2c) RSN, and posterior periaqueductal gray (pPAG) seed to the limb cortex RSN were found to be altered in Tumor 1 Vehicle animals only. Statistical significance was assessed in a linear mixed model testing for group and session interaction as well as for a group effect in session 3 to assess a significant treatment effect (*P , 0.05 and **P , 0.01). FC, functional connectivity; NGF, nerve growth factor; RSN, resting-state network.
the tumor-bearing limb. Seed-based analysis supported these findings and furthermore indicated altered connectivities between the aPAG and pPAG and cortical structures, which are directly linked through the ascending spinothalamic tract.
Connectivities involving thalamic regions were found less affected. This could be attributed to the anesthesia regime comprising medetomidine, which is known to disrupt thalamocortical connectivity in fMRI experiments. 15, 19, 37 The regions mentioned above play important roles in nociceptive transmission and encoding of painful stimuli. As they were found to be unaffected on prospective treatment with anti-NGF treatment, our study indicates the efficacy of such treatments for preventing FC alterations elicited by persistent pain. Although hemispheric lateralization of the amygdala in emotional processing is well documented, its role in pain processing is still not fully understood. As pain comprises a strong emotional and affective component, the amygdala plays a critical role in modulating such components as well as in direct modulation of pain perception. 8 Neurons of the laterocapsular division of the central nucleus of the amygdala (CeLC) have been described to receive specific nociceptive inputs from different body regions in rats. The right amygdala receives input from deep tissue, both hind limbs as well as the tail, whereas left amygdala CeLC neurons respond mostly to nociceptive input in the contralateral hind limb. Nevertheless, electrophysiological studies have found unique activation of the right amygdallar CeLC in response to induction of knee arthritis. 27 On the other hand, a transient increase in left amygdallar activity has been described in a neuropathic pain condition in vivo using electrophysiological recordings, while at late stages of the model the right amygdala was activated predominantly. 17 The discrepancy between those results and our study might arise from the nature of pain derived from bone metastasis that comprises several aspects such as nociceptive, neuropathic, and inflammatory pain rather than being purely neuropathic. In addition, processing of emotional components by amygdallar CeLC neurons has been described to occur predominantly on the right in male subjects, whereas in female subjects these processes occurred predominantly in the left amygdala. 7 More recent studies have also suggested that the right amygdala is predominantly involved in pronociceptive signaling, whereas the left amygdala processes antinociceptive signals. 42 Therefore, our findings might indicate a failing top-down suppression of nociceptive signaling at the last fMRI time point, which has been described to be mediated by the infralimbic medial prefrontal cortex. 40 Cancer pain-associated FC alterations could be successfully prevented through the prospective administration of anti-NGF antibody mAb911 with only few residual interactions. Seed-based analysis indicated no changes in connectivity strength as indicated by Z-scores as a function of time in Tumor 1 anti-NGF mice throughout the observation period. In fact, values were not different from those measured in Sham 1 Vehicle animals at all time points. This indicates on one hand the specificity of FC alterations for tumor-associated persistent pain, and on the other hand the effectiveness of mAb911 treatment in preventing these pathological changes. In addition, control seeds in the ipsilateral amygdallar nucleus did not show previously observed trends, endorsing the validity of obtained results and further underlining their specificity (supplementary Figure 1 , available at http://links.lww.com/ PAIN/A659). Residual alterations, as observed in the ROIbased network analysis, were to be expected as behavioral readouts of pain (guarding) indicated weak but significant spontaneous pain behavior at 20 d.p.i. in the Tumor 1 anti-NGF group. These effects are unlikely due to direct central effect of anti-NGF treatment, as the comparison of Sham 1 Vehicle and Sham 1 anti-NGF mice displayed only minimal differences in FC patterns affecting Mb regions but not painassociated ascending and descending pathways. This is in line with reports stating that NGF target receptors are largely absent from the CNS except from basal forebrain cholinergic neurons, where low levels of TrkA expression were described. 44 The absence of central NGF receptors together with the low CNS penetration of IgG molecules suggests minimal nonspecific effects on FC. Although anti-NGF treatment addresses important aspects of bone cancer pain such as neuropathic and inflammatory nociceptive processes, additional processes not related to NGF such as bone remodeling associated with tumor growth will trigger peripheral mechanical pain stimuli, which might lead to residual FC changes described.
Regarding behavioral readouts, we would like to mention that the difference between tumor-bearing and sham-operated animals regarding the number of flinches and the time spent guarding reported in this study appears low in absolute numbers. This can be attributed to the early time points of measurements (days 13 and 18 after tumor implantation), which have been chosen to investigate early changes in the brain functional architecture in response to nociceptive input. In fact, the behavioral measures of the current study follow the trajectory of developing behavioral signs of pain that has been reported previously for this model, 6 illustrating good reproducibility. Considering the effect size of behavioral symptoms between tumor-bearing and sham-operated animals, our results are in line with results obtained from a similar tibial bone cancer model, although using a different tumor cell line and mouse strain. 28 Differences in absolute values are not surprising, as it has been reported that the extent of behavioral signs of pain depends on the mouse strain used 36 and almost certainly also on the osteolytic potential of the tumor cells. Therefore, comparisons of absolute numbers in behavioral readouts of nociception should be viewed with care.
Prospective treatment using mAb911 effectively prevented FC alterations observed in tumor-bearing untreated animals. It has been previously shown that anti-NGF treatment effectively reverses nerve sprouting, neuroma formation, and nociceptive behavior on preventive administration as well as under a therapeutic treatment regime in mice. 28 Although prospective administration is certainly more effective as it blocks pathological nociceptor alterations before they occur, it typically does not represent the clinical situation. Nevertheless, prospective administration would be desirable also in a clinical setting to effectively prevent such pathological events, thereby counteracting development of a pain state from bone metastasis in affected patients. Thereby, efficacy of anti-NGF antibody mAb911 to reverse FC alterations after their development could be assessed in future studies.
In summary, we could show that anti-NGF treatment using mAb911 not only effectively prevents peripheral nociceptive processes but also showed effects on FC of the brain, as indicated by rs-fMRI. This supports previously published promising effects of anti-NGF antibody mAb911 to effectively prevent and treat cancer-induced skeletal pain.
